此前，外媒上周六报道称，博士伦正在考虑出售，以解决阿波罗全球管理公司(Apollo Global Management)等金融机构对其与母公司Bausch Health(BHC.US)分离提出的担忧。这家加拿大眼科护理公司正与高盛的顾问合作以评估买家兴趣。该公司于2022年从Bausch Health分拆独立。According to foreign media reports, private equity firms are interested in acquiring Bausch Health in the United States (BLCO.US), and as of the time of submission, the stock has risen by 8.51%.
According to the Zhitong Finance and Economics APP, private equity firms, including Blackstone Group, Advent International, TPG Capital, CVC Capital, and Hellman & Friedman, are evaluating potential acquisition offers from Bausch Health. Bidders can express their acquisition intentions before the deadline on Friday.
It is not yet certain that the sale process will result in a final transaction. The company is also exploring other options, including refinancing some of its debt. The potential selling price of Bausch Health is unclear, but it could be higher than the current enterprise value of $11.5 billion, including debt.
Earlier, foreign media reported last Saturday that Bausch Health is considering a sale to address concerns raised by Apollo Global Management and other financial institutions about its separation from its parent company, Bausch Health. The Canadian eyecare company is working with Goldman Sachs advisers to evaluate buyer interests. The company was spun off from Bausch Health in 2022.